Treatment of MuSK antibody-positive myasthenia gravis with rituximab: an exploratory clinical study
Not Applicable
- Conditions
- MuSK antibody-positive myasthenia gravis
- Registration Number
- JPRN-UMIN000012089
- Lead Sponsor
- Department of Neurology University of Tokyo, Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Patients who have severe hypersensitivity or anaphylactic reaction to rituximab or mouse-derived products. (2) Pregnant women or women of possibility of pregnancy. (3) Lactating women. (4) Patients of HBs antigen positive or patients who had HBV infection in their past. (5) Patients of HBs antigen negative and HBc antibody or HBs antibody positive, and detectable HBV-DNA. (6) Patients who have received any other experimental drug or investigational product within three months before the start of study treatment in the present study. (7) Patients who are considered inadequate for this study by Principal investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method We assess the clinical state of patients using a Myasthenia gravis foundation of America post-intervention status (MGFA-PIS), Quantitative MG score for Disease Severity (QMG score), and the amounts of waning of repetitive stimulation tests. A patient is considered to have responded if they have attained an MGFA-PIS of improved, Minimal Manifestations, Pharmacologic Remission or Complete Stable Remission. The effectiveness evaluation is established by the response rate.
- Secondary Outcome Measures
Name Time Method